Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 16


Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.


Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.

Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, Strohmaier C.

Alzheimers Res Ther. 2015 Mar 8;7(1):9. doi: 10.1186/s13195-014-0088-8. eCollection 2015.


Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.

Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C.

Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104.


Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016. Epub 2011 Dec 14.


Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models.

Shen KK, Fripp J, Mériaudeau F, Chételat G, Salvado O, Bourgeat P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2155-66. doi: 10.1016/j.neuroimage.2011.10.014. Epub 2011 Oct 14.


Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Cho Y, Seong JK, Jeong Y, Shin SY; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2217-30. doi: 10.1016/j.neuroimage.2011.09.085. Epub 2011 Oct 8.


BEaST: brain extraction based on nonlocal segmentation technique.

Eskildsen SF, Coupé P, Fonov V, Manjón JV, Leung KK, Guizard N, Wassef SN, Østergaard LR, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2362-73. doi: 10.1016/j.neuroimage.2011.09.012. Epub 2011 Sep 16.


Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators.

Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008. Epub 2011 Apr 3.


Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP.

J Clin Oncol. 2010 Jan 20;28(3):424-30. doi: 10.1200/JCO.2009.25.3724. Epub 2009 Dec 14. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.


Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators.

Cancer. 2009 Feb 1;115(3):551-60. doi: 10.1002/cncr.24066. Erratum in: Cancer. 2010 Aug 1;116(15):3750. Santini, Valeria [added].


Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.

Capdeville R, Krahnke T, Hatfield A, Ford JM, Van Hoomissen I, Gathmann I.

Ann Oncol. 2008 Jul;19(7):1320-6. doi: 10.1093/annonc/mdn050. Epub 2008 Mar 15.


Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group.

Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6.


Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1039-43. Epub 2007 Oct 11. Erratum in: Blood. 2008 Jul 15;112(2):452. Gambacorti, Carlo [corrected to Gambacorti-Passerini, Carlo].


Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F.

Blood. 2006 Sep 1;108(5):1478-84. Epub 2006 Apr 20.


The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW.

Clin Endocrinol (Oxf). 2005 Aug;63(2):176-84.


A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.

van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW.

J Clin Endocrinol Metab. 2004 Feb;89(2):638-45.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk